A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, a Chimeric Anti-GM-CSF Monoclonal Antibody, in Patients with Asthma
Néstor A. Molfino, Geoffrey Yarranton, Philip G. Bardin(Monash Medical Centre), Philip J. Thompson, Alison Luckey(Global Antibiotic Research & Development Partnership)
Cited by 3
Related Papers
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123
Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial
|The Lancet Infectious Diseases|2024|98
Site-specific attachment to recombinant antibodies via introduced surface cysteine residues
|Protein Engineering Design and Selection|1990|66
Tumour targeting of humanised cross-linked divalent-fab′ antibody fragments: a clinical phase I/II study
|British Journal of Cancer|2002|43